BIOMARIN PHARMACEUTICAL INC
For the period ended Dec 31, 2024. Filed Feb 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 24, 2025
BMRN$57.13-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands of U.S. Dollars and share amounts in thousands)
| 2024 | 2023 | 2022 | |
|---|---|---|---|
| Shares of Common Stock, beginning balances | 188,598 | 186,251 | 183,913 |
| Issuances under equity incentive plans | 2,163 | 2,347 | 2,338 |
| Shares of Common Stock, ending balances | 190,761 | 188,598 | 186,251 |
| Total stockholders' equity, beginning balances | $4,951,549 | $4,603,156 | $4,265,669 |
| Common stock: | |||
| Beginning balances | 189 | 186 | 184 |
| Issuances under equity incentive plans, net of tax | 2 | 3 | 2 |
| Ending balances | 191 | 189 | 186 |
| Additional paid-in capital: | |||
| Beginning balances | 5,611,562 | 5,404,895 | 5,191,502 |
| Issuances under equity incentive plans, net of tax | (28,354) | (7,162) | 14,328 |
| Stock-based compensation | 217,493 | 212,828 | 199,895 |
| Change in Common stock held by the Nonqualified Deferred Compensation plan (NQDC) | 1,367 | 1,001 | (830) |
| Ending balances | 5,802,068 | 5,611,562 | 5,404,895 |
| Company common stock held by the NQDC: | |||
| Beginning balances | (9,860) | (8,859) | (9,689) |
| Change in Common stock held by the NQDC | (1,367) | (1,001) | 830 |
| Ending balances | (11,227) | (9,860) | (8,859) |
| Accumulated other comprehensive income (loss): | |||
| Beginning balances | (28,788) | (3,867) | 14,432 |
| Other comprehensive income (loss) | 90,441 | (24,921) | (18,299) |
| Ending balances | 61,653 | (28,788) | (3,867) |
| Accumulated deficit: | |||
| Beginning balances | (621,554) | (789,199) | (930,760) |
| Net income | 426,859 | 167,645 | 141,561 |
| Ending balances | (194,695) | (621,554) | (789,199) |
| Total stockholders' equity, ending balances | $5,657,990 | $4,951,549 | $4,603,156 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.